FLI1
Reactivity: Human
WB, IP
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Western blot: 1-2 μg/m,l
Flow Cytometry: 0.5-1 μg/10^6 cells
IF: 1-2 μg/mL
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the FLI1 antibody to be titered up or down for optimal performance.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.2 mg/mL
Buffer
PBS with 0.1 mg/mL BSA and 0.05 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Aliquot and Store at -20C. Avoid freez-thaw cycles.
Target
FLI1
(Friend Leukemia Virus Integration 1 (FLI1))
Alternative Name
FLI1
Background
Friend leukemia integration 1 is a member of the ETS family of DNA binding transcription factors that is involved in cellular proliferation and tumorigenesis. Members of the Ets gene family share a highly conserved carboxy-terminal domain containing a sequence related to the SV40 large T antigen nuclear localization signal sequence. Approximately 90 % of Ewing's Sarcoma (EWS) / Primitive Neuroectodermal Tumors (PNET) have a specific translocation, t(11,22)(q24,q12), which results in fusion of EWS to Fli-1, and production of an EWS-Fli-1 fusion protein. Among normal tissues only endothelial cells and small lymphocytes express Fli-1. This protein is expressed in majority of vascular tumors including angiosarcomas, hemangioendotheliomas, hemangiomas, and Kaposi's Sarcomas. High sensitivity and specificity of Fli-1 equals to or exceeds that of the established vascular markers like CD31, CD34, and Factor VIII.